News | April 29, 2025
Pfizer Q1 2025 revenue drops 8% to $13.7 billion
Delivers robust earnings performance, successfully navigating a dynamic environment
Delivers robust earnings performance, successfully navigating a dynamic environment
The company has reported total income of Rs. 628.4 crores during the period ended March 31, 2025
Planned acquisition will strengthen the presence of Merck Healthcare in the United States and expand reach of SpringWorks’ therapeutic innovations to more patients with rare tumors worldwide
The positive opinions are based on applications submitted by Biosimilar Collaborations Ireland Limited
The closing of the Block Acquisition is now expected to be completed by Q3 2025
The company has received final approval from the Department of Pharmaceuticals, Government of India, for foreign investment under applicable regulations
Bayer expects 2025 to be the most difficult year of its turnaround
Ami Organics’ Ankleshwar Unit II gets GMP compliant by PMDA Japan
The capital raise will also support debt repayment or prepayment, improving the company's debt-to-equity ratio and overall financial resilience
The company delivered revenues of Rs. 5,554 crore, representing 10% growth in FY25
Subscribe To Our Newsletter & Stay Updated
